Mutational analysis of JAK1 gene in human hepatocellular carcinoma

Neoplasma

Volumn 56, Issue 2, 2009, Pages 136-140

  Xie, H J ^a   Bae, H J ^a   Noh, J H ^a   Eun, J W ^a   Kim, J K ^a   Jung, K H ^a   Ryu, J C ^b   Ahn, Y M ^c   Kim, S Y ^a   Lee, S H ^a   Yoo, N J ^a   Lee, J Y ^a   Park, W S ^a   Nam, S W ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

Hepatocellular carcinoma; JAK1 gene; Mutation

Indexed keywords

JANUS KINASE 1; STAT PROTEIN; JAK1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; JANUS KINASE 1 GENE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DEVELOPMENT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; GENETICS; LIVER TUMOR; MIDDLE AGED; MUTATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; JANUS KINASE 1; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SIGNAL TRANSDUCTION;

EID: 65649096940     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_02_136     Document Type: Article

References (30)

1. Patrick A, Alexio C, Michael K. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair,mitogen- activated protein kinase and JAK/STAT pathways. Journal of Gastroenterology and Hepatology 2000; 15: 357-368. doi:10.1046/j.1440-1746.2000.02069.x (Pubitemid 30262201)
2. Sangro B, Herraiz M, Martinez-Gonzalez MA et al. Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery 1998; 124: 575-583. (Pubitemid 28413356)
3. Satoh S, Daigo Y, Furukawa Y et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24: 245-250 doi:10.1038/73448 (Pubitemid 30132191)
4. De la CA, Romagnolo B, Billuart P et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998; 95: 8847-8851 doi:10.1073/pnas.95.15.8847 (Pubitemid 28350577)
5. Pang A, Ng IO, Fan ST, Kwong YL. Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 2003; 146: 8-15. doi:10.1016/S0165-4608(03)00103-1 (Pubitemid 37117428)
6. Schindler CW, Series introduction. JAK-STAT signaling in human disease. J Clin Invest 2002; 109: 1133-1137.
7. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. oncogene 2000; 19: 5662-5679. doi:10.1038/sj.onc.1203925
8. Leonard WJ, O'Shea JJ. Jaks and STATs. Biological implications. Ann Rev Immunol 1998; 16: 293-322. doi:10.1146/annurev.immunol.16.1.293
9. Darnell JE Jr, Kerr IM, Stark GR. Jak-Stat pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421. doi:10.1126/science.8197455
10. Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol 1995; 6: 1-35. doi:10.1016/S0065-2776(08)60582-9
11. Ihle JN, Witthuhn BA, Quelle FW et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994; 19: 222-227. doi:10.1016/0968-0004(94)90026-4 (Pubitemid 24187246)
12. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285: 1-24. doi:10.1016/S0378-1119(02)00398-0 (Pubitemid 34246317)
13. Darnell JE Jr. Stats and gene regulation. Science 1997; 277: 1630-1635. doi:10.1126/science.277.5332.1630
14. Ann NY. Acad. Pathways in cytokine regulation of hematopoiesis. Sci. Ihle, J 2001; 938: 129-130.
15. Leonard WJ. Role of Jak kinases and STATS in cytokine signal transduction. Int. J. Hematol 2001; 73: 271-277. doi:10.1007/BF02981951
16. Manning G, Whyte DB, Martinez R et al. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934. doi:10.1126/science.1075762 (Pubitemid 35425239)
17. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109(Suppl.): S121-S131. doi:10.1016/S0092-8674(02)00701-8
18. Chen M, Cheng A, Candotti F et al. complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol 2000; 20: 947-956. doi:10.1128/McB.20.3.947-956.2000
19. Saharinen P, K. Takaluoma and Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol 2000; 20: 3387-3395. doi:10.1128/McB.20.10.3387-3395.2000
20. Gauzzi MC, Barbieri G et al. the amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. proc. natl. Acad. Sci. USA 1997; 94: 11839-11844. doi:10.1073/pnas.94.22.11839
21. Haan c, Is'harc H, Hermanns HM et al. Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. J. Biol. Chem 2001; 276: 37451-37458. doi:10.1074/jbc.M106135200
22. Knoops L, Hornakova T, Royer Y et al. JAK kinases overexpression promotes in vitro cell transformation. Oncogene 2007; 1-9.
23. Yasuharu Niwa, Hiroaki Kanda, Yuko Shikauchi et al. Methylation silencing of SocS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005; 24: 6406-6417.
24. Kentaro Inamura, Yasushi Matsuzakib, Naoya Uematsua et al. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-a in hepatocellular carcinoma cell lines. Biochimica et Biophysica Acta 2005; 1745: 401-410.
25. Hiroyuki Fuke a, Katsuya Shiraki a and Kazushi Sugimoto a. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications 2007; 363: 738-744. doi:10.1016/j.bbrc.2007.09.049
26. Calvisi DF, Ladu S, Gorden A et al. Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC. Gastroenterology 2006; 130: 1117-1128. doi:10.1053/j.gastro.2006.01.006
27. Flex E, Petrangeli V, Stella Let al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. The Journal of Experimental Medicine 2008; 205: 751-758. doi:10.1084/jem.20072182 (Pubitemid 351549874)
28. Lee JY, Dong SM, Kim SY et al. A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchow Arch 1998; 433: 305-309. doi:10.1007/s004280050253
29. Rossi MR, Hawthorn L, Platt J et al. Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genetics and Cytogenetics 2005; 161: 97-103. doi:10.1016/j.cancergencyto.2005.02.006
30. Staerk J, Kallin A, Demoulin JB et al. JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation. The Journal of Biological Chemistry 2005; 280: 41893-41899. doi:10.1074/jbc.c500358200